Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that management will participate in the following investor conferences:
Event: Guggenheim’s Innaugural Healthcare Innovation ConferenceDate: November 11-13, 2024
Event: Jefferies London Healthcare ConferenceDate: November 19-21, 2024
Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim and Jefferies representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visitwww.rezolutebio.com.
Contact:
Rezolute, Inc.Christen Baglaneascbaglaneas@rezolutebio.com508-272-6717
Released November 5, 2024